The conversation shifts from diagnosis of multiple myeloma to the various benefits and risks associated with treatment. Dr Chernew comments that multiple myeloma treatment is an area of great innovation, where options for patients are constantly changing.
The conversation shifts from diagnosis of multiple myeloma to the various benefits and risks associated with treatment. Dr Chernew comments that multiple myeloma treatment is an area of great innovation, where options for patients are constantly changing.
Dr Kumar suggests that treatment can be looked at broadly in 2 groups: changes that come due the introduction of new drugs and changes that come because of changes in the understanding of the disease itself. He provides a variety of examples for each category.
“I think it’s exciting that we have new drugs belonging to the same class which can be more easily administered and are more effective, but I think it’s also more important that we activate these new classes of drugs because that is one way of overriding the resistance that these cells develop,” says Dr Kumar.
The bottom line, he says, is that patients have time to see if treatment is working appropriately and working with their biology. Time will also help to determine how long patients will have to adhere to a specific regimen.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More